0,1,2,3,4,5,6
"Table 6.3.3:  Selected studies of post-prostatectomy salvage radiotherapy, stratified by pre-salvage",,,,,,
Study,n,Median FU   (mo),pre-SRT   PSA (ng/mL)   median,RT dose    ADT,bNED/PFS   (year),5-yr. results
"Bartkowiak,   et al. 2018   [1039]",464,71,0.31,66.6 Gy,54% (5.9),73% vs. 56%; PSA   < 0.2 vs. > 0.2 ng/mL    p < 0.0001
"Soto, et al.   2012 [1040]",441,36,< 1 (58%),68 Gy   24% ADT,63/55% (3)   ADT/no ADT,44/40% ADT/no ADT    p < 0.16
"Stish, et al.   2016 [1031]","1,106",107,0.6,68 Gy   16% ADT,50% (5)   36% (10),44% vs. 58%; PSA   < 0.5 vs. > 0.5 ng/mL    p < 0.001
"Tendulkar,    et al. 2016   [1041]","2,460",60,0.5,66 Gy   16% ADT,56% (5),Pre-SRT PSA   71% 0.01–0.2 ng/mL  63% 0.21–0.5 ng/mL  54% 0.51–1.0 ng/mL  43% 1.01–2.0 ng/mL  37% > 2.0 ng/mL    p < 0.001
"Jackson,   et al. 2014   [1042]",448,64,68.4 Gy no ADT,5 yr. DM   post-SRT PSA < 0.1 ng/mL 5%   post-SRT PSA > 0.1 ng/mL 29%   p < 0.0001   5 yr. DSM   post-SRT PSA < 0.1 ng/mL 2%   post-SRT PSA > 0.1 ng/mL 7%   p < 0.0001   OS   post-SRT PSA < 0.1 ng/mL 97%   post-SRT PSA > 0.1 ng/mL 90%   p < 0.0001,,
"Stish,   et al. 2016   [1031]","1,106",107,68 (64.8-70.2) Gy   39% 2D treatment   planning   incl. 16% ADT,5 and 8.9 yr. DM   SRT: PSA < 0.5 ng/mL 7% and 12%   SRT: PSA > 0.5 ng/mL 14% and 23%   p < 0.001   5 and 8.9 yr. DSM   SRT: PSA < 0.5 ng/mL < 1% and 6%   SRT: PSA > 0.5 ng/mL 5% and 10%   p = 0.02 5 and 8.9 yr. OS   SRT: PSA < 0.5 ng/mL 94% and 86%   SRT: PSA > 0.5 ng/mL 91% and 78%   p = 0.14,,
"Tendulkar,   et al. 2016   [1041]","2,460",60,66 (64.8-68.4) Gy   incl. 16% ADT,10-yr. DM (19% all patients)  Pre-SRT PSA  9% 0.01–0.2 ng/mL  15% 0.21–0.5 ng/mL  19% 0.51–1.0 ng/mL  20% 1.01–2.0 ng/mL  37% > 2.0 ng/mL  p < 0.001,,
